Dr. Cameron: prescribed steroids beat black-market peptides on safety
Whether prescribed anabolic-androgenic steroids are categorically safer than black-market peptides because the side-effect profile is better characterized.
Unpopular Opinion: prescribed steroids are far safer than black market peptides. Most have a half century of studies and clinical data. They do have side effects, but they're well understood, unlike most non-GLP peptides Steroids are way more effective to be worth the risks!
We partially agree
Dr. Cam is half-right on the part that matters. The peptide market's sourcing problem is real and consistently underweighted in peptide-influencer discourse. Research-vendor purity, sterility, and labeling are all worse than the FDA-regulated drug supply, full stop. But the framing equivocates 'prescribed' with 'medically supervised AAS use,' which most US AAS use isn't, and 'better understood' with 'safer,' which doesn't follow. AAS at recreational doses have well-characterized cardiovascular, hepatic, lipid, and HPG-axis effects. Well-characterized doesn't mean small.
The case for steroids over black-market peptides depends entirely on what 'steroids' and 'peptides' actually mean in the comparison. Medically-supervised TRT versus research-vendor BPC-157 is a clean win for TRT. Recreational-dose Trenbolone versus FDA-approved tirzepatide for fat loss is the opposite. The sweep here is too broad to do the work the argument wants it to do.
What they’re arguing
- Prescribed steroids have a half-century of studies and clinical data behind them.
- AAS side effects are well-understood, unlike most non-GLP peptides.
- Steroids are more effective than peptides, enough to be worth the risks.
- Black-market peptides are a riskier choice than prescribed steroids.
Where the argument holds, where it bends
- strong The peptide-sourcing premise is correct. Research-vendor peptides routinely have purity, sterility, and labeling problems that FDA-regulated drugs don't, and counterfeit GLP-1-class drugs have been documented with off-target compounds. He's right about this part.
- strong 'Prescribed' is doing a lot of work. In the US, anabolic steroids are Schedule III and rarely prescribed outside TRT for documented hypogonadism. The comparison most readers will hear, 'prescribed steroids' versus 'black-market peptides,' actually maps to 'self-administered AAS sourced through gym pharmacies' versus 'self-administered peptides sourced through research vendors.' Both are unmonitored. The supply chain is the only difference.
- strong 'Better understood' isn't 'safer.' Recreational AAS at body-comp doses have well-characterized cardiovascular morbidity (LV hypertrophy, atherosclerosis acceleration), hepatic effects (especially with oral 17-alpha-alkylated compounds), lipid derangement (HDL crashes are typical), and HPG-axis suppression that takes months to recover. Knowing what the side effects are doesn't make them small.
- moderate 'Most non-GLP peptides' sweeps too broadly. Tesamorelin, sermorelin, semaglutide, tirzepatide, and PT-141 all have meaningful human trial evidence. Thymosin Alpha-1 has EU regulatory approval for hepatitis B. The peptide pipeline includes drugs with decades of trial data. The equivocation collapses 'research-vendor experimental peptides' into 'all non-GLP peptides,' and those aren't the same category.
- moderate Effectiveness depends on the goal. AAS dominates muscle mass and recomp by a wide margin. Peptides dominate specific niches: appetite and glucose via GLP-1s, sexual function via PT-141, gut inflammation via KPV in trial settings. 'Steroids are way more effective' is true for one use case. It isn't a general truth.
- minor The 'half century of studies' framing slightly oversells. Long observational data on AAS in athletic populations is mostly retrospective and confounded by polypharmacy. Controlled trials of supraphysiologic AAS in healthy adults are rare for ethics reasons. The clinical data is for therapeutic-dose hormone replacement, which is a different question than body-comp protocols.